Alphamab Oncology (9966.HK)
Company Info
| ISIN | KYG0330A1013 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | HK$2.12B |
|---|---|
| Total Revenue (TTM) | HK$136.47M |
| Gross Profit (TTM) | HK$103.30M |
| Year Range | HK$2.00 - HK$13.46 |
| Target Price | HK$5.06 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in Alphamab Oncology, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Alphamab Oncology had a return of -67.32% year-to-date (YTD) and -76.52% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -67.32% | 13.20% |
| 1 month | -8.44% | -1.28% |
| 6 months | -56.25% | 10.32% |
| 1 year | -76.52% | 18.23% |
| 5 years (annualized) | N/A | 12.31% |
| 10 years (annualized) | N/A | 10.58% |
Monthly Returns
The table below presents the monthly returns of 9966.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -40.51% | 27.09% | -9.76% | 4.86% | -46.53% | -5.51% | -67.32% | ||||||
| 2023 | 21.11% | 11.01% | -9.23% | 16.08% | -47.71% | -6.50% | 20.19% | -4.00% | -0.35% | 33.72% | -45.13% | 5.23% | -38.52% |
| 2022 | -26.62% | -7.52% | -13.87% | 1.76% | -4.20% | 4.39% | -19.04% | 21.83% | -23.56% | -9.67% | 60.62% | 22.03% | -20.59% |
| 2021 | -18.30% | -1.95% | -13.65% | 26.47% | 41.50% | 23.33% | -13.48% | -6.98% | -11.80% | -8.84% | 18.16% | -28.42% | -16.46% |
| 2020 | -1.29% | 27.21% | -11.83% | 9.68% | 8.59% | -2.38% | -6.77% | -1.55% | -8.34% | 3.17% | -2.94% | 7.25% | 16.29% |
| 2019 | 3.70% | 3.70% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 9966.HK is 7, indicating that it is in the bottom 7% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Alphamab Oncology (9966.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Alphamab Oncology. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alphamab Oncology was 92.18%, occurring on Jul 25, 2024. The portfolio has not yet recovered.
The current Alphamab Oncology drawdown is 92.18%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.18% | Jul 15, 2021 | 746 | Jul 25, 2024 | — | — | — |
| -56.75% | May 21, 2020 | 226 | Apr 20, 2021 | 23 | May 24, 2021 | 249 |
| -30.77% | Feb 27, 2020 | 16 | Mar 19, 2020 | 37 | May 15, 2020 | 53 |
| -22.29% | May 25, 2021 | 9 | Jun 4, 2021 | 13 | Jun 24, 2021 | 22 |
| -13.51% | Dec 17, 2019 | 17 | Jan 13, 2020 | 18 | Feb 10, 2020 | 35 |
Volatility
Volatility Chart
The current Alphamab Oncology volatility is 12.36%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Alphamab Oncology.
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |